Insights

High growth niche VintaBio operates in viral vector development and manufacturing for gene therapy, with recent data presentation at ASGCT and expansion in Philadelphia. Opportunity: target biotech firms advancing AAV, LVV, adenoviral, and Vero-based programs seeking scalable, compliant manufacturing partners to accelerate clinical timelines.

Expanded capacity Recent financing supported a new 22,500 sq ft facility designed for cell and gene therapy manufacturing. Opportunity: present capacity and scale-up capabilities to sponsors facing bottlenecks in preclinical to clinical production, emphasizing process development and adherence to quality.

Strategic partnerships Active collaboration with Wistar Institute for biomedical technician training signals strong ecosystem ties and talent access. Opportunity: offer co-development, technical operations support, and workforce-ready manufacturing programs to potential customers needing reliable teams and transfer of knowledge.

Proprietary efficiency VintaBio claims VintaProcess enables higher yield, purity, and streamlined downstream, with reliable timelines and scalable production without footprint growth. Opportunity: benchmark these efficiencies to potential clients facing cost-per-dose pressure and supply reliability challenges in clinical trials.

Financial viability Funding of $64M and revenue in the multi-million range position VintaBio as a growing, investable partner with proven investor backing. Opportunity: approach as a financially stable collaborator capable of long-term GMP manufacturing commitments and multi-program support, reducing perceived risk for sponsors.

Similar companies to VintaBio

VintaBio Tech Stack

VintaBio uses 8 technology products and services including HubSpot Analytics, WordPress, OneTrust, and more. Explore VintaBio's tech stack below.

Media & News

VintaBio's Email Address Formats

VintaBio uses at least 1 email format:
VintaBio Email FormatsExamplePercentage
FLast@vintabio.comJDoe@vintabio.com
100%

Frequently Asked Questions

What is VintaBio's official website and social media links?

Minus sign iconPlus sign icon
VintaBio's official website is vintabio.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does VintaBio generate?

Minus sign iconPlus sign icon
As of October 2026, VintaBio's annual revenue is estimated to be $10M - $25M.

What is VintaBio's SIC code and NAICS code?

Minus sign iconPlus sign icon
VintaBio's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does VintaBio have currently?

Minus sign iconPlus sign icon
As of October 2026, VintaBio has approximately 32 employees across 1 continents, including North America. Key team members include Chief Executive Officer: D. R., Chief Commercial Officer (cco): J. K. and Vice President Facilities & Engineering: L. G. Explore VintaBio's employee directory with LeadIQ.

What industry does VintaBio belong to?

Minus sign iconPlus sign icon
VintaBio operates in the Biotechnology Research industry.

What technology does VintaBio use?

Minus sign iconPlus sign icon
VintaBio's tech stack includes HubSpot Analytics, WordPress, OneTrust, Osano, Firebase, NetSuite, Shopify and WP Engine.

What is VintaBio's email format?

Minus sign iconPlus sign icon
VintaBio's email format typically follows the pattern of FLast@vintabio.com. Find more VintaBio email formats with LeadIQ.

How much funding has VintaBio raised to date?

Minus sign iconPlus sign icon
As of October 2026, VintaBio has raised $64M in funding. The last funding round occurred on Apr 11, 2023 for $64M.

When was VintaBio founded?

Minus sign iconPlus sign icon
VintaBio was founded in 2020.
VintaBio logo

VintaBio

Biotechnology ResearchPennsylvania, United States11-50 Employees

VintaBio operates as a viral-vector development and manufacturing partner in the biotechnology research sector. It collaborates with biotech and pharmaceutical companies pursuing viral vector programs—including AAV, LVV, adenoviral, and Vero-based platforms—through the transition from early development to clinical testing. The company specializes in adherent manufacturing across preclinical work, IND-enabling studies, process development, and clinical-stage production, aiming to deliver scalable output with consistent quality.

Headquartered in Philadelphia, in the Navy Yard district, the company sits in a region known for cell and gene therapy innovation. Recent activity includes presenting data at the ASGCT annual meeting in 2025 to illustrate the productivity of its VintaProcess approach.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2020
Employees
11-50

Section iconFunding & Financials

  • $64M

    VintaBio has raised a total of $64M of funding over 1 rounds. Their latest funding round was raised on Apr 11, 2023 in the amount of $64M as a Venture Round.

  • $10M - $25M

    VintaBio's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.